Kigen develops synthetic enzyme manufacturing of therapeutics for chronic neuroimmune diseases — making the next generation of treatments scalable and accessible.
Chronic neuroinflammatory diseases affect hundreds of millions worldwide. Current treatments focus on downstream events. Targeting upstream molecular pathways at therapeutic scale has been impossible, until now.
Kigen is building the synbio infrastructure to manufacture effective neuroinflammatory treatments. We combine AI-driven protein engineering with scalable synthetic biology manufacturing processes to produce therapeutic molecules that were previously inaccessible at meaningful scale.
Our platform replaces complex chemical synthesis with single-enzyme precision — enabling production at costs and purities that make global therapeutic access possible.
Explore our platform ↗Our platform combines natural enzymes with computational protein engineering to produce precision fermentation manufacturing — replacing toxic multi-step chemical synthesis with clean single-enzyme processes.
Computational design and machine learning to create optimised enzymes with enhanced activity, selectivity, and stability for therapeutic molecule production.
Clean, single-step enzymatic manufacturing processes that run at 37°C and atmospheric pressure, inputting natural molecules and producing high-purity therapeutics.
Partnership-driven GMP manufacturing with established CDMOs. Pharmaceutical-grade output for nutraceutical and clinical commercial supply chains.
Direct-to-market nutraceuticals and therapeutics targeting chronic neuroinflammatory diseases — including post-TBI, stroke, neuropathic pain, IBD, and neurodegenerative conditions.
Our initial programmes target conditions where chronic neuroinflammation drives disease progression and current treatments remain inadequate.
Chronic inflammation in the central nervous system underlies conditions from traumatic brain injury to neurodegenerative disease. Kigen targets pathways that promote neural recovery and resolution.
Neuropathic and inflammatory pain affects over a billion people globally. Our approach targets the biological mechanisms of resolution rather than symptom suppression.
From autoimmune conditions to post-infectious disorders, chronic immune dysfunction demands new therapeutic approaches targeting upstream molecular pathways.
Inflammaging is a systemic driver of progressive tissue damage, especially in the brain where low-grade chronic neuroinflammation is a major contributor to age-related neurodegeneration.
Chronic inflammatory disease affects billions. Therapeutics can target upstream mechanisms to turn off inflammation, but only if we can manufacture these molecular tools at scale. Kigen is building the synthetic manufacturing processes to make that possible.